Skip to main content

Table 5 Anemia response rate

From: Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study

 

ND

HD

PD

Treatment-naïve patients

N

678

111

66

 Response rate, n (%; 95% CI)

441 (65.04; 61.32–68.63)

60 (54.05; 44.33–63.55)

51 (77.27; 65.30–86.68)

 No effect, n (%)

237 (34.95)

51 (45.94)

15 (22.72)

Patients switched from EPO

N

160

399

20

 Response rate, n (%; 95% CI)

109 (68.12; 60.30–75.25)

279 (69.92; 65.16–74.38)

12 (60.00; 36.05–80.88)

 No effect, n (%)

51 (31.87)

120 (30.07)

8 (40.00)

Patients switched from DA

N

265

383

146

 Response rate, n (%; 95% CI)

162 (61.13; 54.97–67.03)

256 (66.84; 61.87–71.53)

99 (67.80; 59.58–75.29)

 No effect, n (%)

103 (38.86)

127 (33.15)

47 (32.19)

  1. Effectiveness: cases in which Hb levels reached ≥ 10.0 g/dL, and Hb levels increased by ≥ 1.0 g/dL until week 24
  2. Effectiveness: cases in which Hb levels were maintained within a range between 10.0 to 12.0 g/dL at week 48
  3. DA darbepoetin alfa, EPO erythropoietin, Hb hemoglobin, HD hemodialysis, ND not on dialysis, PD peritoneal dialysis